• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZONG Yungang. Analysis and suggestions on the development trend of drug innovation in China[J]. Journal of China Pharmaceutical University, 2023, 54(3): 380-388. DOI: 10.11665/j.issn.1000-5048.20220906001
Citation: ZONG Yungang. Analysis and suggestions on the development trend of drug innovation in China[J]. Journal of China Pharmaceutical University, 2023, 54(3): 380-388. DOI: 10.11665/j.issn.1000-5048.20220906001
shu

Analysis and suggestions on the development trend of drug innovation in China

  • National Medical Products Administration Institute of Medical Economics, Guangzhou 510140, China

More Information
  • Received Date: September 05, 2022
  • Revised Date: May 05, 2023
    Graphical Abstract
    • Abstract
  • In order to comprehensivehy evaluate the stage of China in the global drug innovation, to further optimize the environment for drug innovation in China, and to unleash the vitality of drug innovation, this article mainly analyzes through comparison China''s situation of drug innovation in global competition from such perspectives as the current situation of the global drug R&D innovation market, R&D investment, product pipeline, policy support, and development trends, combined with the characteristics of China''s drug innovation development.It can be seen that China''s pharmaceutical innovation is faced with such practical problems as lagging behind some developed countries in terms of innovation development, companies bunching into research and development innovation, sudden research and development rush, and excessive dependence on capital markets for pharmaceutical innovation.Accordingly, this paper puts forward suggestions on continuously improving China''s new drug innovation environment, rationally selecting differentiated competition and new tracks, reasonably formulating drug innovation development strategies, guiding capital to return to innovative research and development, and constructing a "double cycle" strategy for drug innovation.
    • FullText(HTML)
    • References (14)
  • [1]
    Lloyd I.Pharma R&D Annual Review 2020[EB/OL].(2020-07-18)[2021-09-12]. https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2020/files/whitepapers/rd-review-2020-whitepaper-update.pdf.
    [2]
    Li R, Meng J, Zhao RC, et al. Analysis of research and development status of new drugs in 2022[J]. Chin Bull Life Sci (生命科学), 2023, 35(1): 80-87.
    [3]
    Frost & Sullivan. China CRO Industry Market Research Report.[EB/OL][2020-06-19].https://www.frostchina.com/content/insight/detail?id=62f366d357d0761f000a3433.
    [4]
    BDO. Revenue, R&D and biotech''s future[EB/OL]. [2021-12-20]. https://www.bdo.com/BDO/media/Misc-Documents/LS_Biotech-Brief-Report_Summer-2021_WEB.pdf.
    [5]
    Deloitte. Seeds of change: measuring the return from pharmaceutical innovation 2020[EB/OL]. (2021-07-20)[2021-12-20]. https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-sciences-health-care /deloitte-uk-measuring-the-return-from-pharmaceutical-innovation-2021.pdf.
    [6]
    Chen J, Dong Z. Influence and countermeasures and suggestions of medical outsourcing in China on the basis of drug registration system reform[J]. China Pharm (中国药业), 2018, 27(23): 70-73.
    [7]
    Wu X, Shao R. Current situation and analysis of venture capital of innovative medicine[J]. Chin J Pharm (中国医药工业杂志), 2020, 51(8): 1070-1079.
    [8]
    Fu P, Lu JJ, Sun SY. Discussion on prospect of pharmaceutical innovation market and development of CRO industry in 2020[J]. Tianjin Sci Technol (天津科技), 2020, 47(5): 94-96.
    [9]
    Yao W, Yan JZ, Shao R. A study on the evaluation criteria of medical insurance negotiation admittance for innovative drugs in typical countries and its enlightenment to China[J]. Chin J New Drugs (中国新药杂志), 2021, 30(12): 1057-1062.
    [10]
    Yin SQ, Zhang H, Liu YH. The effect of policy implementation and some relevant suggestions on the inclusion of innovative tumor drugs in the national reimbursement drug list[J]. Chin Health Econ (中国卫生经济), 2021, 40(1): 22-24.
    [11]
    IQVIA. Global trends in R&D: overview through 2020[EB/OL]. (2021-05-19)[2021-10-02]. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d.
    [12]
    China Pharmaceutical Innovation and Research Development Association (PhIRDA), R&D-Based Pharmaceutical Association Committee (RDPAC). Promoting simultaneous R&D, registration and review of innovative drugs, fostering pharmaceutical innovation system in China[J]. China Food Drug Administ Magaz (中国食品药品监管), 2022, 7(222): 4-13.
    [13]
    Chen H, Chen PX. The hidden worries of "assault R&D"[J].Bus Manage (企业管理), 2020, 5: 48-53.
    [14]
    Sun TY. China''s pharmaceutical innovation has entered the second tier globally[J].China Econ Week (中国经济周刊), 2022, 5: 62-64.
    • Related Articles

  • Related Articles

    [1]CAI Xu, WU Xiaoqian, HAN Lingfei, FENG Feng, QU Wei, LIU Wenyuan. Research progress on natural products regulating osteogenic differentiation[J]. Journal of China Pharmaceutical University, 2025, 56(1): 10-21. DOI: 10.11665/j.issn.1000-5048.2024101003
    [2]MA Lei, YANG Zhaoqing, WANG Youchun. Progress and prospect of global vaccine research and development[J]. Journal of China Pharmaceutical University, 2024, 55(1): 115-126. DOI: 10.11665/j.issn.1000-5048.2023121601
    [3]XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
    [4]CHEN Yi, ZHUANG Qian, CHU Shuzhen. Research on exporting competitiveness of pharmaceuticals in China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 120-126. DOI: 10.11665/j.issn.1000-5048.20190117
    [5]WANG Juan, LIAO Hong. Advances in drug research and development through directed differentiation of stem cells[J]. Journal of China Pharmaceutical University, 2011, 42(3): 193-197.
    [6]Effects of panaxatriol saponins on the differentiation and apoptosis of MC3T3-E1 cells[J]. Journal of China Pharmaceutical University, 2010, 41(3): 273-377.
    [7]The Sensibility of Human Glioma Cell to Seven Differentiation Inducing Agents.[J]. Journal of China Pharmaceutical University, 2002, (5): 66-70.
    [8]Effect of Penetration Enhancers on the Thermal Transition of Hydrated Callus Lipid in the Study of Differential Scanning Calorimetry[J]. Journal of China Pharmaceutical University, 1994, (2): 92-95.
    [9]Determination of Weakly Alkaline Drugs by Differential Scanning Potentiometry Titration[J]. Journal of China Pharmaceutical University, 1992, (6): 354-356.
    [10]ASSAY OF CAPTOPRIL TABLETS BY DIFFERENTIAL SPECTROPHOTOMETRY[J]. Journal of China Pharmaceutical University, 1989, (2): 97-99.

  • Cited by

    Periodical cited type(9)

    1. 于飞，卢静，高辰旭，李敬伟. 中外创新药物医保支付的比较研究. 医药导报. 2024(03): 470-476 .
    2. 刘亚琴，张梦晓，初绽，杨心督. 着力优化创新政策环境 助力医药产业高质量发展——我国药品研发创新态势分析及思考. 价格理论与实践. 2024(05): 82-86+222 .
    3. 周增娜，徐莉莉，盛威午. 我院药学部中西药物管理的现状与优化策略. 中医药管理杂志. 2024(13): 84-86 .
    4. 陈功，罗艳，叶连宝. 以培养创新药物研究人才为目标的药物化学教学改革. 药学教育. 2024(05): 43-46 .
    5. 高松. 中美创新药产业格局对比分析及对拉动中国经济增长的启示. 广东经济. 2024(19): 66-71 .
    6. 党子悦，张钰，谈维，郭冬梅. 2015年至2023年我国审评上市药品分析. 中国药业. 2024(23): 6-11 .
    7. 吕倩鹏，吴红，刘智勇. 政策工具视角下我国创新药物研发政策量化研究. 中国卫生事业管理. 2024(12): 1393-1399 .
    8. 刘曙霞，王琰，杨爽，王雅晴，胥美美. 中国创新药物研发现状与发展建议（英文）. Chinese Medical Sciences Journal. 2024(04): 288-297 .
    9. 高慧. 新质生产力驱动下西部城市生物医药产业发展研究——以昆明市为例. 云南科技管理. 2024(06): 40-43 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (138) PDF downloads (373) Cited by(9)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：304033

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return